Northern Trust Corp raised its stake in Express Scripts Holding Co (NASDAQ:ESRX) by 0.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,205,190 shares of the company’s stock after buying an additional 40,656 shares during the quarter. Northern Trust Corp owned about 1.82% of Express Scripts worth $787,943,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the company. Landaas & Co. WI ADV acquired a new stake in Express Scripts in the second quarter valued at approximately $102,000. Kaizen Advisory LLC raised its holdings in Express Scripts by 147.6% in the second quarter. Kaizen Advisory LLC now owns 1,342 shares of the company’s stock valued at $104,000 after acquiring an additional 800 shares in the last quarter. Wealthcare Advisory Partners LLC raised its holdings in Express Scripts by 364.7% in the first quarter. Wealthcare Advisory Partners LLC now owns 1,529 shares of the company’s stock valued at $106,000 after acquiring an additional 1,200 shares in the last quarter. Adviser Investments LLC raised its holdings in Express Scripts by 321.9% in the second quarter. Adviser Investments LLC now owns 1,481 shares of the company’s stock valued at $114,000 after acquiring an additional 1,130 shares in the last quarter. Finally, Sun Life Financial INC raised its holdings in Express Scripts by 758.8% in the second quarter. Sun Life Financial INC now owns 1,520 shares of the company’s stock valued at $117,000 after acquiring an additional 1,343 shares in the last quarter. 84.73% of the stock is currently owned by institutional investors and hedge funds.
Shares of ESRX traded up $0.55 during mid-day trading on Friday, reaching $94.29. 2,922,063 shares of the company’s stock were exchanged, compared to its average volume of 4,316,647. The company has a current ratio of 0.71, a quick ratio of 0.59 and a debt-to-equity ratio of 0.69. The firm has a market cap of $53.41 billion, a PE ratio of 13.28, a price-to-earnings-growth ratio of 1.20 and a beta of 1.01. Express Scripts Holding Co has a 52-week low of $55.80 and a 52-week high of $97.22.
Express Scripts (NASDAQ:ESRX) last announced its earnings results on Wednesday, August 1st. The company reported $2.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.20 by $0.02. Express Scripts had a net margin of 4.65% and a return on equity of 25.49%. The business had revenue of $25.64 billion for the quarter, compared to analyst estimates of $25.43 billion. During the same period last year, the firm posted $1.73 earnings per share. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. As a group, equities research analysts forecast that Express Scripts Holding Co will post 9.07 EPS for the current fiscal year.
In related news, insider Christine Houston sold 12,898 shares of the stock in a transaction on Friday, August 10th. The stock was sold at an average price of $85.00, for a total transaction of $1,096,330.00. Following the completion of the sale, the insider now directly owns 110,908 shares of the company’s stock, valued at $9,427,180. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.79% of the stock is owned by company insiders.
Several brokerages have commented on ESRX. BidaskClub lowered shares of Express Scripts from a “hold” rating to a “sell” rating in a research note on Saturday, July 21st. ValuEngine upgraded shares of Express Scripts from a “hold” rating to a “buy” rating in a research note on Monday, September 17th. Credit Suisse Group lowered shares of Express Scripts from an “outperform” rating to a “neutral” rating and increased their price target for the company from $90.00 to $96.50 in a research note on Tuesday, September 18th. Zacks Investment Research lowered shares of Express Scripts from a “hold” rating to a “sell” rating in a research note on Monday, July 23rd. Finally, William Blair upgraded shares of Express Scripts from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 1st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Express Scripts presently has a consensus rating of “Hold” and a consensus target price of $86.36.
Express Scripts Company Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Featured Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.